S-1/A: AIM ImmunoTech Launches $12M Rights Offering Amid NYSE Listing Concerns

AIM ImmunoTech Inc. is conducting a non-transferable rights offering to raise up to $12 million for general corporate purposes, clinical trials, and debt repayment, while facing NYSE American listing non-compliance.

Summary

• AIM ImmunoTech Inc. is an immuno-pharma company focused on developing therapeutics for cancers, viral diseases, and immune-deficiency disorders, with its flagship product Ampligen (rintatolimod).
• The company is launching a non-transferable subscription rights offering to raise up to $12 million in gross proceeds by offering 12,000 Units at $1,000 per Unit.
• Each Unit consists of one share of Series G Convertible Preferred Stock (convertible into common stock at $1.20/share) and 1,666 Warrants (exercisable for common stock at $1.20/share, expiring in five years).
• The offering is on a "best-efforts" basis with no minimum amount of proceeds required to close, meaning the company may raise substantially less than the maximum target.
• Proceeds are intended for general corporate purposes, including clinical trial expenses for prospective Phase 2/3 pancreatic cancer trials, manufacturing expenses, and repayment of existing debt obligations.
• The company reported a negative net tangible book value of approximately $8.12 million, or negative $2.94 per share, as of September 30, 2025.
• AIM ImmunoTech is not in compliance with NYSE American's stockholders' equity rule, with a deficit of approximately negative $6.1 million as of September 30, 2025, and must regain compliance by June 11, 2026, to avoid delisting.
• The board of directors is making no recommendation regarding the exercise of the Subscription Rights, and exercises are irrevocable.
• Maxim Group LLC is acting as the dealer-manager, receiving an 8.0% cash fee on gross proceeds and up to $125,000 for expenses.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing with cautious optimism. While the clinical trial data for Ampligen shows promise in challenging indications like pancreatic and ovarian cancer, the company's significant financial distress, negative net tangible book value, and NYSE listing non-compliance present substantial risks. The capital raise is critical but also highly dilutive and lacks a minimum guarantee.

Positives

• Ampligen has shown promising results in clinical testing for pancreatic cancer, with a Netherlands study indicating extended survival beyond standard of care.
• The DURIPANC Phase 1b/2 trial for late-stage pancreatic cancer reported positive mid-year safety and efficacy in July 2025, with no significant toxicity in 14 subjects, 21% progression-free survival >6 months, and 64% overall survival >6 months in eligible subjects.
• A Phase 2 trial for recurrent platinum-sensitive ovarian cancer showed an Objective Response Rate (ORR) of 50% (5 complete responses, 7 partial responses out of 24 evaluable patients) when Ampligen was combined with pembrolizumab and cisplatin.
• Pre-clinical and clinical work supports Ampligen's broad-spectrum antiviral capabilities, including positive results against SARS-CoV-2 and potential for avian influenza combination therapy with FluMist.
• The AMP-518 Phase 2 study for Post-COVID conditions met enrollment targets and reported topline data in February 2024, with final results posted in January 2025, supporting Ampligen as a potential therapeutic for moderate-to-severe Post-COVID fatigue.
• Preliminary results from an open-label expanded access protocol for ME/CFS and Post-COVID conditions showed clinically significant decreases in fatigue and improved cognition by week 12.

Negatives

• The company has a negative net tangible book value of approximately $8.12 million, or negative $2.94 per share, as of September 30, 2025.
• AIM ImmunoTech is not in compliance with NYSE American's stockholders' equity rule, with a deficit of approximately negative $6.1 million as of September 30, 2025, and faces potential delisting if compliance is not regained by June 11, 2026.
• The Rights Offering is on a "best-efforts" basis with no minimum amount of proceeds, meaning the company may not raise sufficient capital to meet its objectives.
• The offering is expected to cause immediate and substantial dilution to the net tangible book value of common stock for purchasers, estimated at $1.00 per share.
• Non-participating stockholders will experience a decrease in their proportionate ownership interest.
• There is no public trading market for the Series G Convertible Preferred Stock or the Warrants, and the company does not intend to apply for listing, limiting liquidity for these new securities.
• The market price of common stock may decrease during or after the Rights Offering, and the market price may never exceed the Warrant exercise price of $1.20 per share.
• The company has not declared or paid dividends to stockholders since inception and does not plan to in the foreseeable future.

Risks

• Management will have broad discretion over the use of net proceeds, and funds may not be invested successfully.
• Stockholders and securities holders who do not fully exercise their Subscription Rights will experience dilution of their proportional ownership interest.
• The Rights Offering is on a best-efforts basis with no minimum, meaning the company may raise significantly less than the maximum, potentially insufficient to meet business objectives.
• The Rights Offering may cause the trading price of common stock to decrease, and the availability of shares for future sale from Warrants could depress the market price.
• Holders of Preferred Stock and Warrants will have no rights as common stockholders until conversion or exercise.
• The company may terminate the Rights Offering at any time, in which case only subscription payments will be returned without interest.
• The Subscription Price is not an indication of the fair value of the common stock.
• Failure to follow subscription instructions or timely payment may result in rejection of exercise.
• Subscribers may not receive all Units for which they subscribe due to proration, especially if the offering is over-subscribed.
• Personal checks may not clear in sufficient time, leading to rejection of subscription.
• The receipt of Subscription Rights may be treated as a taxable distribution for U.S. federal income tax purposes, contrary to the company's belief.
• Proposed changes in U.S. tax law may adversely impact the company and the value of its securities.
• Exercising Subscription Rights limits the ability to engage in certain hedging transactions.
• Subscription Rights are non-transferable, and there is no market for them.
• Warrants, as executory contracts, may have no value in a bankruptcy or reorganization proceeding.
• The terms of the Rights Offering may be amended or modified by the board at any time prior to expiration.
• The company is not in compliance with NYSE American continued listing requirements (stockholders' equity below $6 million) and faces potential delisting if compliance is not regained by June 11, 2026.

Future Outlook

The company intends to prioritize clinical work in trials authorized by the FDA or EMA, supporting potential future New Drug Applications (NDAs). Specifically, it plans to use proceeds for prospective Phase 2/3 pancreatic cancer clinical trials and is exploring a second Ampligen and FluMist study in humans for avian influenza, seeking collaborative grants. The company also believes Ampligen is a potential therapeutic for moderate-to-severe Post-COVID fatigue and will be the likely subject population for any follow-up clinical trial.

Management Comments

• "We are prioritizing activities in an order related to the stage of development, with those clinical activities such as pancreatic cancer having priority over other experimentation."
• "We intend that priority clinical work be conducted in trials authorized by the FDA or European Medicines Agency (EMA), which trials support a potential future NDA."
• "We believe that this pre-clinical and clinical work to date — combined with the ever-growing threat of Avian influenza — strongly supports our decision to move forward with this second Ampligen and FluMist study in humans."
• "The results support our belief in Ampligen as a potential therapeutic for people with the moderate-to-severe Post-COVID condition of fatigue, and that this would be the likely subject population for any follow-up clinical trial."
• "Our board of directors is making no recommendation regarding your exercise of the Subscription Rights. You should carefully consider whether to exercise your Subscription Rights before the expiration date."

Industry Context

StockSavvy.ai notes that AIM ImmunoTech operates in the highly competitive and capital-intensive immuno-pharma sector, focusing on niche areas like pancreatic cancer, ME/CFS, and antiviral therapies. The positive early-stage clinical data for Ampligen in pancreatic and ovarian cancers, particularly in combination with checkpoint inhibitors, aligns with a broader industry trend towards combination therapies to enhance anti-tumor responses. The pursuit of therapies for Post-COVID conditions and avian influenza also positions the company in areas of significant public health interest, potentially attracting government and industry grants, similar to how larger players like AstraZeneca (partnered in DURIPANC and avian influenza studies) engage in collaborative research to de-risk development and expand market reach. However, the company's financial instability and reliance on capital raises are common challenges for small-cap biotech firms, contrasting with the robust funding and diversified pipelines of industry giants.

Comparison to Industry Standards

• The 50% Objective Response Rate (ORR) in the Phase 2 ovarian cancer trial (Ampligen + pembrolizumab + cisplatin) is a notable result, especially for recurrent platinum-sensitive ovarian cancer. For comparison, single-agent pembrolizumab in recurrent ovarian cancer typically shows ORRs in the range of 6-10%, while combination therapies can vary widely. For instance, bevacizumab plus chemotherapy in recurrent ovarian cancer has shown ORRs around 30-40%. The 50% ORR suggests a potentially superior efficacy profile for AIM's combination, though direct comparisons require larger, randomized trials.
• The progression-free survival (PFS) >6 months in 21% of subjects and overall survival (OS) >6 months in 64% of eligible subjects in the DURIPANC Phase 1b/2 pancreatic cancer trial are encouraging for a late-stage disease with poor prognosis. Standard of care (e.g., FOLFIRINOX or gemcitabine/nab-paclitaxel) for metastatic pancreatic cancer typically yields median OS of 8-12 months. While the DURIPANC data is from a small, early-stage trial, the statistically significant data from the Netherlands study (Ampligen alone) indicating extended survival beyond SOC provides a strong signal, warranting further investigation in larger trials, similar to how companies like Merck (with Keytruda) or Bristol Myers Squibb (with Opdivo) build evidence for their immuno-oncology agents.

Corporate Governance

Related Party Transactions

• Recent sales of unregistered securities (common stock) were made to officers, directors, employees, and consultants (including Nancy Bryan, David Chemerow, Thomas Equels, William Mitchell, Peter Rodino, and Ted Kellner) at various prices and dates, deemed exempt from registration under Section 4(a)(2) or Rule 701.

Stakeholder Impact

• **Shareholders**: Existing shareholders who do not participate will experience significant dilution. Participating shareholders will incur investment risk on new money and face immediate dilution in net tangible book value. All shareholders face the risk of delisting from NYSE American if compliance is not regained.
• **Employees/Management**: Current officers and directors are entitled to participate in the Rights Offering on the same terms as other rights holders. Some have received unregistered securities as compensation.
• **Creditors**: A portion of the net proceeds from the Rights Offering is allocated to repay certain existing debt obligations, which could improve the company's debt profile.
• **Patients/Medical Community**: The capital raise aims to fund ongoing clinical trials for Ampligen in various cancers and viral diseases, potentially leading to new therapeutic options if successful.

Next Steps

• Continue enrollment and dosing in Phase 2 of the DURIPANC clinical trial for late-stage pancreatic cancer.
• Potentially redesign or amend the suspended Phase 2 pancreatic cancer study, pending additional data from DURIPANC.
• Pursue a study of a potential avian influenza combination therapy of Ampligen and AstraZeneca's FluMist, seeking collaborative grants.
• Conduct follow-up clinical trials for Ampligen as a potential therapeutic for moderate-to-severe Post-COVID condition of fatigue.
• Regain compliance with NYSE American's stockholders' equity rule by June 11, 2026, to avoid delisting.
• Close on subscriptions for the Rights Offering as soon as practicable after February 27, 2026 (or extended date).
• Issue shares of Preferred Stock and Warrants purchased in the Rights Offering in book-entry form after closing.

Key Dates

Recommendation

The company is at a critical juncture, balancing promising early-stage clinical data for Ampligen across multiple high-need indications with severe financial challenges, including negative stockholders' equity and a looming NYSE delisting threat. The Rights Offering is a necessary but dilutive capital raise with no minimum guarantee. While the scientific potential warrants continued observation, the significant financial and market risks suggest a 'hold' for existing investors, advising against new speculative positions until there is clearer progress on both clinical development and financial stability, particularly regaining NYSE compliance.

Keywords

AIM ImmunoTech, Ampligen, Rintatolimod, Immuno-oncology, Pancreatic cancer, Ovarian cancer, Viral diseases, COVID-19, Long COVID, ME/CFS, Avian influenza, Rights Offering, Preferred Stock, Warrants, Capital raise, Dilution, NYSE American, Delisting risk, Biotechnology, Pharmaceuticals, Clinical trials